Neurology Book

//fpnotebook.com/

Myasthenia Gravis

Aka: Myasthenia Gravis, Erb-Goldflam Gravis, Myasthenic Crisis, Generalized Myasthenia, Ocular Myasthenia Gravis
  1. See Also
    1. Neuromuscular Junction
    2. Lambert-Eaton Syndrome
    3. Ptosis
    4. Diplopia
    5. Muscle Weakness
  2. Pathophysiology
    1. Neuromuscular Autoimmune Disease
    2. Antibodies form to nicotinic acetylcholine receptors (as well as other Antigens, e.g. Muscle specific Tyrosine Kinase)
      1. Affects post-synaptic membrane of the Neuromuscular Junction
      2. Results in post-synaptic membrane receptor internalization and decreased skeletal Muscle response
    3. Results in fluctuating and variable, progressive weakness and true fatigability
    4. Associated with thymoma in up to 25% of cases
  3. Epidemiology
    1. Annual Incidence: 10-20 new cases per million (60,000 cases in U.S.)
    2. Prevalence: 14 to 40 cases per 100,000 in U.S. (similar to worldwide Prevalence)
    3. Age of onset (multimodal)
      1. Neonatal Myasthenia Gravis (transient related to maternal antibodies)
      2. Ages 20-30 (predominantly female)
      3. Ages 50-80 (predominantly male)
  4. Types
    1. Ocular Myasthenia Gravis
      1. Eyelid weakness (Ptosis)
      2. Extraocular Muscle Weakness (Diplopia)
      3. Seronegative in 50% of cases
      4. Progresses to Generalized Myasthenia gravis within 2 years in 50% of cases
    2. Generalized Myasthenia Gravis
      1. Includes facial Muscle and extraocular Muscle Weakness as above AND
      2. Bulbar weakness (Dysarthria, Dysphonia, Dysphagia, fatigable chewing)
      3. Extremity weakness (proximal Muscle Weakness)
      4. Respiratory Muscle Weakness (includes Myasthenia Crisis, see below)
      5. Seronegative in 10% of cases
    3. Other forms
      1. Thymoma-associated Myasthenia Gravis
  5. Associated Conditions
    1. Neuromyelitis optica
    2. Autoimmune Thyroid disease
    3. Systemic Lupus Erythematosus
    4. Rheumatoid Arthritis
  6. Risk Factors: Medication Triggers for Myasthenia Gravis and Myasthenia crisis
    1. Magnesium
    2. Beta Blockers
    3. Calcium Channel Blockers
    4. Statins
    5. Class Ia Antiarrhythmics (e.g. Quinidine, Procainamide, Amiodarone)
    6. High-dose Corticosteroids
    7. Haloperidol
    8. Prochlorperazine
    9. Phenytoin
    10. Antihistamines
    11. IV Contrast (risk 3% with low osmolarity contrast, increased risk with older, higher osmolarity agents)
    12. Antibiotics
      1. Fluoroquinolones (e.g. Ciprofloxacin)
      2. Aminoglycosides (e.g. Gentamicin)
      3. Macrolides (e.g. Azithromycin)
  7. Risk Factors: Other Triggers for Myasthenia Gravis and Myasthenia crisis
    1. Infection
      1. Infection triggering myasthenia is common
      2. Consider empiric antibiotics (see safe antibiotics below)
    2. Electrolyte abnormalities
    3. Trauma
    4. Surgery
    5. Thyroid disease
    6. Pregnancy
  8. Presentations
    1. Early course
      1. Typically transient with symptom free intervals lasting days to weeks
    2. Ocular Myasthenia Gravis (50%)
      1. Ptosis (80% of cases)
      2. Diplopia (vertical or horizontal)
    3. Bulbar symptoms or Generalized Phase (15%)
      1. Dysarthria
      2. Dysphagia
      3. Fatigable chewing
    4. Isolated motor weakness (<5%)
      1. Proximal Muscle Weakness
      2. Other sites of isolated Muscle Weakness are less common presentations
        1. Neck weakness
        2. Distal limb weakness
        3. Respiratory Muscle Weakness
  9. Symptoms
    1. Muscle Weakness provoked by exertion
    2. May be precipitated by infection, fever, stress and other acute factors
    3. Ocular weakness
      1. Eyelid Muscle Weakness resulting in Ptosis (unilateral or bilateral)
        1. May increase with sustained upward gaze
      2. Extraocular Muscle Weakness resulting in binocular Diplopia (vertical or horizontal)
        1. Resolves with covering one eye
      3. Pupil reaction is always spared in ocular myasthenia
    4. Bulbar weakness
      1. Fatigable chewing (often mid-way through a meal)
        1. Patient may need to use their fingers to lift the jaw, and close the mouth
      2. Dysarthria
        1. Nasal quality or low intensity voice
      3. Dysphagia
        1. Difficulty Swallowing liquids and solids
        2. Aspiration may occur with myasthenia crisis
      4. Nasal regurgitation
        1. Occurs if Palate weak
    5. Facial Muscle Weakness
      1. Loss of expression (especially loss of smile, or sneer appearance)
    6. Neck Muscle Weakness
      1. Neck flexor Muscle Weakness
      2. Neck extensor Muscle Weakness
        1. May give "dropped head" appearance with head flexed over chest later in the day
    7. Extremity Muscle Weakness (asymmetric)
      1. Arms affected more than legs
      2. Proximal Muscle Weakness are typically more affected than distal Muscles
      3. Distal wrist extensors and foot dorsiflexors are most often involved
      4. Normal Deep Tendon Reflexes
      5. Normal Sensation
    8. Respiratory Muscle Weakness
      1. Respiratory insufficiency may progress to Respiratory Failure (myasthenia crisis)
      2. Patient initially compensates for decreased lung excursion (due to Muscle Weakness) with Tachypnea
      3. Orthopnea may be present (gravity when upright may aid diaphragm excursion)
      4. Progression from Dyspnea to Tachypnea to reaspiratory arrest may be rapid
        1. Close monitoring of respiratory status is critical (see myasthenia crisis below)
  10. Signs
    1. See symptoms above
    2. Muscle Weakness as above
    3. Deep Tendon Reflexes normal
    4. Respiratory function (see below)
      1. Pulmonary Function Assessment of Respiratory Muscle Strength
        1. Single Breath Counting
        2. Forced Vital Capacity (FVC)
        3. Negative Inspiratory Flow (NIF) or Maximal Inspiratory Pressure (MIP)
      2. Respiratory Muscle Weakness
        1. Tachypnea
        2. Hypophonia
        3. Intercostal Muscle and diaphragm weakness
        4. Accessory Muscle use or paradoxical breathing
        5. Intercostal retractions
        6. Abnormal lung sounds (e.g. Stridor)
      3. Bulbar weakness
        1. Unable to swallow secretions
        2. Difficulty holding head up
        3. Difficult phonation
    5. Specific Tests
      1. Ice Pack Test
        1. Cold pack applied to eye with Ptosis for 2 minutes
        2. Myasthenia Gravis related Ptosis improves (at least 2 mm) with cold applied
        3. Test Sensitivity 90% for Myasthenia Gravis
      2. Tensilon Test (Edrophonium Test)
        1. Acetylcholinesterase Inhibitor given and Motor Strength improves in Myasthenia Gravis
        2. Rarely performed due to lack of edrophonium (FDA discontinued drug in 2018 for poor Specificity)
  11. Labs: Specific Antibody
    1. Seronegative Myasthenia Gravis occurs in 6-12% of cases (most frequently Ocular Myasthenia Gravis)
    2. Acetylcholine Receptor Antibody (AChR-Ab)
      1. Binding AChR-Ab is typically used as it has best efficacy
        1. Blocking AChR-Ab may be indicated in some cases due to its high Specificity
        2. Modulating AChR-Ab may slightly increase Test Sensitivity but at the risk of False Positives
      2. Present in 50% of Ocular Myasthenia Gravis
      3. Present in 80-90% of Generalized Myasthenia gravis
    3. Muscle-Specific Receptor Tyrosine KinaseAntibody (MuSK-Ab)
      1. Absent in most cases of Ocular Myasthenia Gravis
      2. Present in 38-50% of Generalized Myasthenia gravis patients who are AChR-Ab negative
  12. Labs: Other testing
    1. Serum Electrolytes
    2. Thyroid Function Test
      1. Hyperthyroidism (3-8%)
    3. Electromyogram (EMG)
      1. Decremental response to repetitive nerve stimulation
    4. CT neck or MRI neck
      1. Thymoma evaluation
    5. Rheumatoid Factor (RF)
    6. Antinuclear Antibody (ANA)
  13. Differential Diagnosis
    1. Contrast with unique features of Myasthenia Gravis
      1. Ptosis and weak extraocular Muscles (e.g. Diplopia)
      2. Bulbar weakness (Dysphonia, Dysarthria, Dysphagia)
      3. Proximal Muscle Weakness (chewing Fatigue, neck Muscles, proximal extremities)
      4. Preserved normal Sensation, pupil reaction, Deep Tendon Reflexes
      5. No increased secretions, Autonomic Dysfunction, or muscle Fasciculations
    2. Ocular Myasthenia Gravis mimics
      1. Hyperthyroidism (including Thyroid ophthalmopathy)
      2. Kearns-Sayre Syndrome
      3. Brainstem lesions
    3. Generalized Myasthenia gravis mimics
      1. Amyotrophic Lateral Sclerosis (ALS)
      2. Lambert-Eaton Syndrome
        1. Associated with cancer, and typically affects proximal extremity Muscle Weakness
      3. Botulism
      4. Neurasthenia
      5. Intracranial Mass lesion with extraocular affect
    4. Drug-induced Myasthenia (distinguish from medications that exacerbate mysathenia, see above)
      1. Penicillamine
      2. Polymyxin
      3. Tetracycline
      4. Aminoglycosides
      5. Procainamide
      6. Propranolol
      7. Phenothiazine
      8. Lithium
  14. Complications
    1. Aspiration Pneumonia
    2. Cholinergic crisis (excessive Acetylcholinesterase Inhibitor)
      1. See Cholinergic Toxicity
    3. Myasthenia Crisis (30% of cases)
      1. See Below
  15. Management: General
    1. Eliminate triggers (esp. medications, see above)
      1. Many of the triggering medications may be used with caution, at lowest effective dose in stable patients
      2. Exercise caution with CNS Depressants (e.g. Opioids, Benzodiazepines)
        1. Risk of respiratory depression
    2. Correct Electrolyte abnormalities
    3. Support airway and respiratory status as needed
      1. See myasthenia crisis evaluation as above
      2. BiPAP may be used to support respirations before requiring Endotracheal Intubation in alert patient
      3. In RSI, avoid paralysis with depolarizing medications (Succinylcholine)
        1. Use nondepolarizing agents (but consider 50% of typical dose due to increased sensitivity)
  16. Management: Medication
    1. First-Line: Anticholinesterase (Cholinergic)
      1. Provides symptomatic relief
        1. Most effective on extremity weakness and bulbar symptoms
        2. Less effective on Ptosis
        3. Least effective on Diplopia
      2. Adverse Effects
        1. Risk of Cholinergic Toxicity
        2. Risk of worsening myasthenia crisis (due to mucous plugging, bronchorrhea)
      3. Pyridostigmine Bromide (Mestinon)
        1. Child: 0.5 to 1 mg/kg every 4-6 hours (maximum 7 mg/kg/day divided every 4 to 6 hours)
        2. Adult
          1. Starting Dose: 30 mg three times daily
          2. Typical Dose: 60 to 90 mg every 4 to 6 hours while awake
          3. Maximum Dose: 120 mg every 4 hours while awake
        3. Pharmacokinetics
          1. Onset: 15-30 minutes
          2. Peaks: 2 hours
          3. Duration: 3-4 hours
      4. Neostigmine
        1. Less commonly used
    2. Second-Line: Immunosuppressants
      1. Prednisone
        1. Risk of worsening decompensation in early management
        2. Start at 20 mg orally daily
        3. Increase gradually by 5 mg every 3 days to 60mg
        4. Continue for 3 months OR
          1. Until clinical improvement stops or declines
        5. Taper gradually to every other day
      2. Azathioprine (Imuran)
        1. Dosing
          1. 2 mg/kg/day
        2. Efficacy
          1. Effective when given with Prednisone
          2. Effect not seen for 6 months or more
        3. Monitoring
          1. Complete Blood Count (CBC)
          2. Liver Function Tests (LFT)
      3. Mycophenolate mofetil (Cellcept)
        1. Has been used for Myasthenia Gravis roughly since 2000, but evidence of benefit is lacking
        2. Heatwole (2008) Neuropsychiatr Dis Treat 4(6):1203-9 +PMID: 19337460 [PubMed]
    3. Third-Line: Immunosuppressants (refractory to second-line agents)
      1. Cyclophosphamide (Cytoxan)
      2. Rituximab (Rituxan)
      3. Efgartigimod (Vyvgart)
        1. Antibody fragment binds neonatal Fc receptor (FcRn) and prevents recycling of IgG
        2. Lowers IgG Levels (including AChR antibodies in Myasthenia Gravis)
  17. Management: Myasthenia Crisis
    1. Rapidly progressive skeletal Muscle Weakness with risk of Acute Respiratory Failure (Bellows Failure)
      1. Be prepared for emergent Endotracheal Intubation and Mechanical Ventilation
      2. Pyridostigmine is not typically recommended in myasthenia crisis
        1. May exacerbate airway and respiratory complications due to Cholinergic Toxicity effects
        2. May increase bronchorrhea and muous plugging
      3. Monitor frequent Pulmonary Function Assessment of Respiratory Muscle Strength
        1. Negative Inspiratory Flow (NIF) or Maximal Inspiratory Pressure (MIP)
        2. Forced Vital Capacity (FVC)
        3. Single Breath Counting
    2. Signs of impending Acute Respiratory Failure (see exam above)
      1. See Pulmonary Function Assessment of Respiratory Muscle Strength
      2. Negative Inspiratory Flow (NIF) less negative than -20 to 30 cm H2O
      3. Single Breath Counting <10 to 15 (normally >40)
        1. Assess how high a patient can count after a single inspiration
      4. Forced Vital Capacity (FVC)
        1. Normal FVC > 60 cc/kg
        2. Abnormal FVC < 30 cc/kg
        3. Intubate for FVC < 10 cc/kg (or inability to control secretions, respiratory Fatigue)
    3. Respiratory Support in Acute Respiratory Failure
      1. Bilevel Positive Pressure Ventilation
        1. May be trialed before Mechanical Ventilation in alert and oriented patients
        2. Hypercapnia predicts failed BiPAP and need for Mechanical Ventilation
        3. Myasthenia Gravis are high risk for Aspiration Pneumonitis (monitor closely)
        4. Seneviratne (2008) Arch Neurol 65(1): 54-8 [PubMed]
      2. Endotracheal Intubation and Mechanical Ventilation
        1. Depolarizing agents (e.g. Succinylcholine) are less potent in Myasthenia Gravis
        2. Nondepolarizing agents (e.g. Rocuronium) are preferred for Rapid Sequence Intubation (RSI)
          1. Use lower doses in Myasthenia Gravis
    4. Plasmapheresis (Plasma Exchange, PLEX) and Intravenous Immunoglobulin
      1. Indicated for emergent worsening or myasthenia crisis
      2. Response rate: 70%
      3. Plasmapheresis onset of action is rapid
      4. Intravenous Immunoglobulin has longer duration of action
  18. Management: Thymectomy
    1. Indications
      1. Age <60 years
      2. Inadequately controlled on Pyridostigmine
      3. Thymoma discovered
    2. Effect
      1. Clinical improvement after thymectomy in 80%
      2. Benefits may not be seen for 6 months
      3. Transcervical thymectomy may be preferred
    3. References
      1. Calhoun (1999) Ann Surg 230:555-61 [PubMed]
  19. Precautions
    1. Avoid antibiotics that significantly exacerbate neuromuscular weakness
      1. Alternative safe antibiotics include Penicillins, Cephalosporins, carbapenems, Doxycycline, Clindamycin
      2. Aminoglycosides
      3. Fluoroquinolones
      4. Telithromycin (Ketek)
      5. Macrolides (Erythromycin, Azithromycin) - less effect than other agents above
    2. Avoid miscellaneous agents that exacerbate neuromuscular weakness
      1. Magnesium
      2. Class Ia Antiarrhythmics (e.g. Quinidine, Procainamide, Amiodarone)
      3. High-dose Corticosteroids
      4. Iodinated Contrast Dye (seen primarily with older contrast dyes)
    3. References
      1. Hayes in Herbert (2015) 15(9):14
  20. References
    1. Bird (2013) Myasthenia Gravis, in Shefner and Targoff, UpToDate, Wolters Kluwer
    2. Long and Gottleib in Herbert (2021) EM:Rap 21(9): 7-10
    3. (2022) Presc Lett 29(4): 23
    4. Keesey (2004) Muscle Nerve 29:484 [PubMed]
    5. Roper (2017) J Emerg Med 53(6):843-53 +PMID: 28916122 [PubMed]

Myasthenia Gravis (C0026896)

Definition (MEDLINEPLUS)

Myasthenia gravis is disease that causes weakness in the muscles under your control. It happens because of a problem in communication between your nerves and muscles. Myasthenia gravis is an autoimmune disease. Your body's own immune system makes antibodies that block or change some of the nerve signals to your muscles. This makes your muscles weaker.

Common symptoms are trouble with eye and eyelid movement, facial expression and swallowing. But it can also affect other muscles. The weakness gets worse with activity, and better with rest..

There are medicines to help improve nerve-to-muscle messages and make muscles stronger. With treatment, the muscle weakness often gets much better. Other drugs keep your body from making so many abnormal antibodies. There are also treatments which filter abnormal antibodies from the blood or add healthy antibodies from donated blood. Sometimes surgery to take out the thymus gland helps.

For some people, myasthenia gravis can go into remission and they do not need medicines. The remission can be temporary or permanent.

If you have myasthenia gravis, it is important to follow your treatment plan. If you do, you can expect your life to be normal or close to it.

NIH: National Institute of Neurological Disorders and Stroke

Definition (NCI_NCI-GLOSS) A disease in which antibodies made by a person's immune system prevent certain nerve-muscle interactions. It causes weakness in the arms and legs, vision problems, and drooping eyelids or head. It may also cause paralysis and problems with swallowing, talking, climbing stairs, lifting things, and getting up from a sitting position. The muscle weakness gets worse during activity, and improves after periods of rest.
Definition (NCI) A chronic autoimmune neuromuscular disorder characterized by skeletal muscle weakness. It is caused by the blockage of the acetylcholine receptors at the neuromuscular junction.
Definition (MSH) A disorder of neuromuscular transmission characterized by weakness of cranial and skeletal muscles. Autoantibodies directed against acetylcholine receptors damage the motor endplate portion of the NEUROMUSCULAR JUNCTION, impairing the transmission of impulses to skeletal muscles. Clinical manifestations may include diplopia, ptosis, and weakness of facial, bulbar, respiratory, and proximal limb muscles. The disease may remain limited to the ocular muscles. THYMOMA is commonly associated with this condition. (Adams et al., Principles of Neurology, 6th ed, p1459)
Definition (CSP) disease characterized by progressive weakness and exhaustibility of voluntary muscles without atrophy or sensory disturbance and caused by an autoimmune attack on acetylcholine receptors at the neuromuscular junction.
Concepts Disease or Syndrome (T047)
MSH D009157
ICD9 358.0
ICD10 G70.0, G70.00
SnomedCT 193208002, 155092009, 91637004
LNC LA15158-1
Dutch myasthenia gravis paralytica, gravis; myasthenie, myasthenie; gravis, myasthenia gravis, Myasthenia gravis
French Myasthénie grave pseudo-paralytique, Myasthénie grave, Myasthénie, Myasthénie auto-immune, Myasthénie autoimmune
German Myasthenia gravis paralytica, Myasthenia gravis
Italian Miastenia gravis paralitica, Miastenia gravis, Miastenia grave
Portuguese Miastenia grave paralítica, Miastenia Grave, Miastenia grave, Miastenia Gravis
Spanish Miastenia gravis paralítica, miastenia gravis, SAI, miastenia gravis, SAI (trastorno), enfermedad de Erb - Goldflam, miastenia grave, miastenia gravis (trastorno), miastenia gravis, Miastenia gravis, Miastenia Gravis
English Myasthenia Gravis, MYASTHENIA GRAVIS, MG, myasthenia gravis (diagnosis), myasthenia gravis, Myasthenia gravis paralytica, Myasthenia gravis NOS, Myasthenia Gravis [Disease/Finding], myasthenia gravis (MG), myasthenia gravis disorder, Myasthenia gravis NOS (disorder), Erb-Goldflam disease, Myasthenia gravis, MG - Myasthenia gravis, Myasthenia gravis (disorder), Erb-Goldflam, Goldflam-Erb, gravis; myasthenia, myasthenia; gravis, Myasthenia gravis, NOS
Japanese 麻痺性重症筋無力症, ジュウショウキンムリョクショウ, マヒセイジュウショウキンムリョクショウ, 重症筋無力症, 筋無力症, 筋無力症-重症
Swedish Myasthenia gravis
Czech myasthenia gravis, Myasthenia gravis, Myastenia gravis, myastenie gravis
Finnish Myasthenia gravis
Russian MIASTENIIA GREVIS, MIASTENIIA TIAZHELAIA PSEVDOPARALITICHESKAIA, ERBA-GOL'DFLAMA BOLEZN', MIASTENIIA, MYASTHENIA GRAVIS, МИАСТЕНИЯ, МИАСТЕНИЯ ГРЭВИС, МИАСТЕНИЯ ТЯЖЕЛАЯ ПСЕВДОПАРАЛИТИЧЕСКАЯ, ЭРБА-ГОЛЬДФЛАМА БОЛЕЗНЬ
Korean 중증 근육무력증
Croatian MIASTENIJA GRAVIS
Polish Nużliwość mięśni rzekomoporaźna, Miastenia
Hungarian Myasthenia gravis paralytica, Myasthenia gravis
Norwegian Myasthenia gravis
Sources
Derived from the NIH UMLS (Unified Medical Language System)


Myasthenic crisis (C0270942)

Concepts Disease or Syndrome (T047)
ICD9 358.01
ICD10 G70.01
SnomedCT 80976008
Italian Crisi miastenica
Japanese 重症筋無力症クリーゼ, ジュウショウキンムリョクショウクリーゼ
English myasthenia gravis with acute exacerbation (diagnosis), myasthenia gravis with acute exacerbation, Myasthna gravs w ac exac, Myasthenia gravis in crisis, Myasthenia gravis with (acute) exacerbation, Myasthenic crisis, Myasthenic crisis (disorder), Myasthenia gravis crisis
Czech Myastenická krize
Hungarian Myasthenia gravis crisis
Spanish crisis miasténica (trastorno), crisis miasténica, Crisis de miastenia gravis
Portuguese Crise de miastenia grave
Dutch myasthenia gravis-crisis
French Crise myasthénique grave
German myasthenische Krise
Sources
Derived from the NIH UMLS (Unified Medical Language System)


Generalized myasthenia (C0472367)

Concepts Disease or Syndrome (T047)
SnomedCT 230686005
English Generalised myasthenia, Generalized myasthenia, Generalized myasthenia (disorder)
Spanish miastenia generalizada (trastorno), miastenia generalizada
Sources
Derived from the NIH UMLS (Unified Medical Language System)


Myasthenia Gravis, Ocular (C0751340)

Concepts Disease or Syndrome (T047)
MSH D009157
SnomedCT 230684008
Italian Miastenia oculare, Miastenia grave oculare, Miastenia gravis oculare
Japanese 眼筋無力症, ガンキンムリョクショウ
French Myasthénie oculaire
Czech Oční myastenie, okulární myasthenia gravis
English Ocular Myasthenia Gravis, ocular myasthenia gravis, gravis myasthenia ocular, ocular myasthenia, myasthenia ocular, Ocular myasthenia, Ocular myasthenia (disorder), Myasthenia Gravis, Ocular
Hungarian Ocularis myasthenia
Norwegian Okulær myasthenia gravis
Spanish miastenia ocular (trastorno), miastenia ocular, Miastenia ocular
Portuguese Miastenia ocular
Dutch oculaire myasthenie
German Okulaere Myasthenie
Sources
Derived from the NIH UMLS (Unified Medical Language System)


You are currently viewing the original 'fpnotebook.com\legacy' version of this website. Internet Explorer 8.0 and older will automatically be redirected to this legacy version.

If you are using a modern web browser, you may instead navigate to the newer desktop version of fpnotebook. Another, mobile version is also available which should function on both newer and older web browsers.

Please Contact Me as you run across problems with any of these versions on the website.

Navigation Tree